Interventions comprised placebo or recombinant GH injections three times a week , with daily oral placebo or oral EE2 during childhood ( 25 ng/kg/d , ages 5-8 y ; 50 ng/kg/d , ages > 8-12 y ) ; after age 12 , all patients received escalating EE2 starting at a nominal dosage of 100 ng/kg/d .